Anebulo Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2021 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Anebulo Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to 2024.
  • Anebulo Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.41M, a 5.17% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$8.18M, a 30.2% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$8.31M, a 29.5% increase from 2023.
  • Anebulo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$11.8M, a 72.5% decline from 2022.
  • Anebulo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$6.83M, a 89% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$8.31M +$3.47M +29.5% Jul 1, 2023 Jun 30, 2024 10-K 2024-09-25
2023 -$11.8M -$4.95M -72.5% Jul 1, 2022 Jun 30, 2023 10-K 2024-09-25
2022 -$6.83M -$3.22M -89% Jul 1, 2021 Jun 30, 2022 10-K 2023-09-22
2021 -$3.61M Jul 1, 2020 Jun 30, 2021 10-K 2022-09-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.